CMT-PSAT1

PSAT1 | 2023

What Is CMT-PSAT1?

CMT-PSAT1 is a type of CMT caused by autosomal dominant or autosomal recessive mutations in the PSAT1 gene. This gene provides instructions for making an enzyme in the pathway that produces the amino acid serine, which supports nerve cell function. Mutations in the PSAT1 gene disrupt this function, leading to impaired nerve signal transmission.

CMT-PSAT1 can be either autosomal dominant or autosomal recessive, meaning that sometimes it’s just one of the gene’s two copies with a CMT-causing mutation, and sometimes it’s both copies.

Clinical Features

The age of symptom onset in CMT-PSAT1 is variable, ranging from childhood to adulthood. Symptoms typically begin in the lower extremities and progress over time to involve the upper limbs. Nerve conduction studies usually show somewhat slowed conduction velocities and reduced amplitudes, consistent with an axonal form of CMT.

CMT-PSAT1 symptoms may include:

  • Weakness in the feet and lower legs
  • Muscle atrophy
  • Foot drop
  • Reduced or absent reflexes
  • Reduced sensation
  • A steppage-style walking pattern
  • Foot deformities, including high arches, and hammertoes (clawed toes)
  • Progressive involvement of the hands and forearms
  • Difficulty with fine motor skills and manual dexterity
  • Additional symptoms not listed here

Disease Course

CMT-PSAT1 shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
CMT-PSAT1

Classification
Unclassified Subtypes

Neuropathy Type
Axonal

Inheritance Pattern
autosomal dominant, autosomal recessive

Genetic Context

HGNC-Approved Gene Symbol
PSAT1

Gene Full Name
Phosphoserine Aminotransferase 1

HGNC Gene Alias(es)
PSAT

Chromosome
9q21.2

Zygosity of Responsible Variant
Homozygous or Compound Heterozygous

Variant Mechanism
Loss of Function (LoF)

ClinVar Pathogenic Variants

View CMT-PSAT1 ClinVar Variants

PSAT1 OMIM Entry

PSAT1 OMIM

More Info

CMT-PSAT1 Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Pathogenic PSAT1 Variants and Autosomal Recessive Axonal Charcot-Marie-Tooth Disease with Ichthyosis

Authors

Lu, Y., Xing, H., Liu, C., Huang, D., Sun, C., Yu, M., Meng, L., Lv, H., Zhang, W., Wang, Z.,
Yuan, Y., & Xie, Z.

Publication Date
March 1, 2023

Updated: July 18, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.


Illustrated cover graphic showing a split landform with branching directional arrows, two people with question marks above their heads, and the title ‘SORD Deficiency: Decoding This Newly Discovered and Confusing CMT Subtype.


CMT-SORD: What Is This Unique CMT Subtype?

CMT-SORD is a newly discovered CMT subtype driven by toxic sorbitol accumulation. This article explains how "SORD" works, why this subtype is different, and how it led to the fastest-moving therapeutic program in CMT history.